Search Results - "Rangwala, Fatima A."

Pediatric Plexiform Neurofibromas: Impact on Morbidity and Mortality in Neurofibromatosis Type 1 by Prada, Carlos E., MD, Rangwala, Fatima A., MD, Martin, Lisa J., PhD, Lovell, Anne M., MSN, CNP, Saal, Howard M., MD, Schorry, Elizabeth K., MD, Hopkin, Robert J., MD

“…Objective To characterize morbidity, mortality, and surgical outcomes in pediatric patients with symptomatic plexiform neurofibromas (PNFs). Study design We…”
Get full text

A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer by Strickler, John H, Rushing, Christel N, Niedzwiecki, Donna, McLeod, Abigail, Altomare, Ivy, Uronis, Hope E, Hsu, S David, Zafar, S Yousuf, Morse, Michael A, Chang, David Z, Wells, James L, Blackwell, Kimberly L, Marcom, P Kelly, Arrowood, Christy, Bolch, Emily, Haley, Sherri, Rangwala, Fatima A, Hatch, Ace J, Nixon, Andrew B, Hurwitz, Herbert I

“…Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical…”
Get full text

Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer by Lakhani, Nehal J., Stewart, Daphne B., Richardson, Debra L., Dockery, Lauren E., Van Le, Linda, Call, Justin A, Rangwala, Fatima A., Scholl, Anya, Wang, Guanfang, Ma, Bo, Metenou, Simon, Gonzalez, Louis, Pandite, Arundathy, Hamilton, Erika P.

“…5544 Background: SIRPα-Fc-CD40L is a hexameric, bi-functional fusion protein consisting of SIRPα linked to CD40L via an inert Fc linker. This molecule…”
Get full text

Role of adjuvant chemotherapy following chemoradiation and surgery for locoregionally advanced rectal cancer: A Veterans Health Administration analysis by Spiegel, Daphna, Boyer, Matthew, Hong, Julian C., Williams, Christina D., Kelley, Michael J., Rangwala, Fatima A., Salama, Joseph Kamel, Palta, Manisha

“…Abstract only 741 Background: Adjuvant chemotherapy (AC) following chemoradiation (CRT) and total mesorectal excision (TME) for locoregionally advanced rectal…”
Get full text

Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC) by Subbiah, Vivek, Kreitman, Robert J., Wainberg, Zev A., Cho, Jae Yong, Schellens, Jan H.M., Soria, Jean-Charles, Wen, Patrick Y., Zielinski, Christoph, Urbanowitz, Gladys, Mookerjee, Bijoyesh, Wang, Dazhe, Rangwala, Fatima A., Keam, Bhumsuk

“…Abstract only 6023 Background: ATC is a rare, aggressive malignancy with a dismal prognosis. Median overall survival (OS) is < 6 mo. Combined BRAF and MEK…”
Get full text

ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E–mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy by Subbiah, Vivek, Bang, Yung-Jue, Lassen, Ulrik Niels, Wainberg, Zev A., Soria, Jean-Charles, Wen, Patrick Y., Zenz, Thorsten, Moreau, Philippe, Brunsvig, Paal, De Braud, Filippo G., De Greve, Jacques, De Jonge, Maja J., Hofheinz, Ralf D., Italiano, Antoine, Stein, Alexander, Willenbacher, Wolfgang, Schellens, Jan H.M., Zielinski, Christoph, Rangwala, Fatima A., Kreitman, Robert J.

“…Abstract only…”
Get full text

X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC) by Strickler, John H., Rangwala, Fatima A., Rushing, Christel, Niedzwiecki, Donna, Altomare, Ivy, Uronis, Hope Elizabeth, Hsu, Shiaowen David, Zafar, Yousuf, Morse, Michael, Chang, David Z., Wells, James Leroy, Blackwell, Kimberly L., Marcom, P. Kelly, Webb, Anna Renee, Dropkin, Evan, Arrowood, Christy, Hurwitz, Herbert

“…Abstract only 687 Background: Patients (pts) with chemotherapy refractory mCRC have a poor prognosis, with a median survival of approximately 6 months (mos)…”
Get full text

Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) by Atreya, Chloe Evelyn, Van Cutsem, Eric, Bendell, Johanna C., Andre, Thierry, Schellens, Jan H. M., Gordon, Michael S., McRee, Autumn Jackson, O'Dwyer, Peter J, Muro, Kei, Tabernero, Josep, van Geel, Robin, Sidhu, Roger, Greger, James G, Rangwala, Fatima A., Motwani, Monica, Wu, Yuehui, Orford, Keith W., Corcoran, Ryan Bruce

“…Abstract only…”
Get full text

Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC) by O'Reilly, Eileen Mary, Smith, Lon S., Bendell, Johanna C., Rangwala, Fatima A., Schmidt, William, Stephenson, Joe, Kapoun, Ann, Xu, Lu, Hill, Dawn, Zhou, Lei, Dupont, Jakob, Cohn, Allen Lee

“…Abstract only 220 Background: OMP-59R5, a fully human IgG2 antibody, inhibits signaling of Notch2 and 3 receptors. Tumor regression was seen in Notch3…”
Get full text

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors by Rangwala, Fatima A., Bendell, Johanna C., Kozloff, Mark, Arrowood, Christy, Meadows, Jennifer, Tourt-Uhlig, Sandra Ellen, Murphy, Jennifer, Meadows, Kellen, Morse, Michael, Uronis, Hope Elizabeth, Hsu, Shiaowen David, Zafar, Yousuf, Hurwitz, Herbert

“…Abstract only 490 Background: Everolimus (E), an oral rapamycin analogue, is a potent mTOR inhibitor. Combined inhibition of VEGF and mTOR pathways may…”
Get full text